There are emerging data suggesting that cases previously classified as Myelodysplastic syndromes (MDSs) or MDS/myeloproliferative neoplasms (MPNs) with NPM1 progress to AML shortly. This evidence concerns the gene NPM1 and myelodysplastic syndrome.